Eli Lilly and Co

Semaglutide, branded as Ozempic, is a new diet drug originally developed for type 2 diabetes, now used off-label for obesity, causing weight loss up to 17% in 68 weeks. Popular among celebrities and influencers, it has led to shortages and backlash. Side effects include acid reflux and nausea, and weight regain upon cessation. Despite concerns, it may become more widely approved for obesity treatment.

FDA approves Ebglyss, a targeted interleukin-13 inhibitor for moderate-to-severe atopic dermatitis, offering clear skin in 38% of patients at 16 weeks and itch relief in 43% at 16 weeks, with maintenance dosing.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Roche's subcutaneous Tecentriq approved for cancer treatment; Gilead's twice-yearly HIV shot reduces infection risk by 96%; Biogen appoints Lloyd Minor and Menelas Pangalos as independent directors; Sanofi secures rights to a rare cancer radiopharmaceutical; Eli Lilly to expand Irish manufacturing for Alzheimer's drug Kisunla.

The FDA approved Roche's subcutaneous formulation of Tecentriq, branded as Tecentriq Hybreza, making it the first SC anti-PD-(L)1 cancer immunotherapy in the U.S. The SC option reduces treatment time to about 7 minutes compared to 30-60 minutes for IV infusion and is available for all Tecentriq indications.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Three biotech IPOs priced; Voranigo, a brain cancer pill, offers new hope; GLP-1 drugs show potential for type 1 diabetes; Gilead's lenacapavir reduces HIV infection risk; Summit's immunotherapy success discussed; Senators scrutinize misleading drug promotion; insurers scale back on Medicare Advantage; Ozempic sales lead to insurer demands for refunds; compounded semaglutide raises public health concerns.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.